drugset / Trial / NCT00240643
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
RandomizedParallel-groupDouble-blindPrevention
Summary
This study will allow determination of the pharmacokinetic and pharmacodynamics of SB424323 in a relevant population. The data from this study will be used along with other data to aid in choosing the most appropriate dose for the later phase study.
Timeline
- Start
- 2005-11
- Primary completion
- 2006-12
- Completion
- 2006-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SB424323 | Unknown | 250 mg | — |
| Subject | SB424323 | Unknown | 375 mg | — |
| Subject | SB424323 | Unknown | 500 mg | — |